Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia.
Hotaka IshizuTomohiro ShimizuYusuke OhashiKenichi KusunokiMasahiro KanayamaNorimasa IwasakiFumihiro OhaPublished in: Journal of bone and mineral metabolism (2024)
Hypozincemia may reduce the efficacy of DMAb and eldecalcitol in increasing BMD and fracture prevention.